On July 13, 2021 Evrys Bio, a biotech company developing Next Gen Antivirals, reported the company was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents (Press release, Evrys Bio, JUL 13, 2021, View Source [SID1234644911]). The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses. Evrys Bio’s broad-spectrum antiviral technology is based on the discovery that certain human proteins, called sirtuins, normally defend the human (host) cell from being invaded by pathogens. The novel drug will target the human SIRT-2 protein.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The DOD’s Defense Threat Reduction Agency’s Chem Bio Technologies, Vaccines and Therapeutics Division executed an Other Transaction Authority (OTA) agreement with Evrys for this effort. The milestone-based agreement anticipates five years of development from drug-prototype identification to proof-of-concept and regulatory filings.
"EVRYS stands for the Company’s vision to ultimately address every virus," said Lillian Chiang, PhD, CEO, Evrys Bio. "This DTRA collaboration addresses highly lethal viral infection and extends our pipeline that already includes developing products to treat pan-respiratory, pan-hepatic, and pan-opportunistic viral infections."